ALX Oncology
ALXOALXO · Stock Price
Historical price data
Overview
ALX Oncology is a clinical-stage biotech focused on developing evorpacept, a next-generation CD47 inhibitor engineered to minimize toxicity while promoting macrophage-mediated tumor destruction. The company's core strategy is to develop evorpacept as a synergistic backbone therapy in combination with established and emerging oncology agents, with multiple Phase 2 trials underway. Key achievements include establishing proof-of-concept in gastric cancer and securing strategic collaborations with major pharmaceutical partners to expand its clinical reach.
Technology Platform
Engineered CD47-blocking fusion protein platform designed to inhibit the 'don't eat me' signal on cancer cells with an inactive Fc domain to minimize toxicity, promoting macrophage-mediated phagocytosis in combination with antibody-based therapies.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Evorpacept (ALX148) + Trastuzumab + Paclitaxel + Capecitabin... | Breast Cancer, Metastatic | Phase 1/2 | |
| Evorpacept (ALX148) + Pembrolizumab + Trastuzumab + Rituxima... | Metastatic Cancer | Phase 1 | |
| evorpacept + venetoclax + azacitidine | Acute Myeloid Leukemia | Phase 1 | |
| evorpacept + azacitidine | Higher Risk Myelodysplastic Syndromes | Phase 1 | |
| ALX2004 + ALX2004 + ALX2004 | NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
ALX competes in the challenging CD47/SIRPα inhibitor space against first-generation agents with toxicity issues and novel approaches from other biotechs. Its key differentiation is evorpacept's engineered safety profile and extensive combination trial network. Broader competition includes any new therapy aiming to become a standard combination partner in immuno-oncology.